[
  {
    "ts": null,
    "headline": "Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q2 2025 Update",
    "summary": "Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q2 2025 Update",
    "url": "https://finnhub.io/api/news?id=58c187a768f5bc4c3434410510e342c2b411f0a5ea7e700bddd565110013faf7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755818681,
      "headline": "Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q2 2025 Update",
      "id": 136473977,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=58c187a768f5bc4c3434410510e342c2b411f0a5ea7e700bddd565110013faf7"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Shares Rally as Pharma Giant Invests $2 Billion in U.S. Expansion",
    "summary": "JNJ Stock Moves Higher as Pharma Leader Strengthens Domestic Supply Chain",
    "url": "https://finnhub.io/api/news?id=0385536056b028d93490548811fa542756de1ca0a9e0024f48f26453633cbcde",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755802156,
      "headline": "Johnson & Johnson Shares Rally as Pharma Giant Invests $2 Billion in U.S. Expansion",
      "id": 136471490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ Stock Moves Higher as Pharma Leader Strengthens Domestic Supply Chain",
      "url": "https://finnhub.io/api/news?id=0385536056b028d93490548811fa542756de1ca0a9e0024f48f26453633cbcde"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at approximately USD 478.83 Billion in 2024 and is expected to reach USD 527.36 Billion in 2025 and is expected to reach around USD 1,320.19 Billion by 2034, at a CAGR of 10.42% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen Inc., P",
    "url": "https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755793800,
      "headline": "[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136467561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at approximately USD 478.83 Billion in 2024 and is expected to reach USD 527.36 Billion in 2025 and is expected to reach around USD 1,320.19 Billion by 2034, at a CAGR of 10.42% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen Inc., P",
      "url": "https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78"
    }
  },
  {
    "ts": null,
    "headline": "J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub",
    "summary": "The deal is part of a wider $55bn investment strategy by J&J to bolster US manufacturing amid pressure from Trump.",
    "url": "https://finnhub.io/api/news?id=615a33857129581ee822ff8224aa506412088defdb6ac986dd8c38eca6a1767c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755791935,
      "headline": "J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub",
      "id": 136467594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The deal is part of a wider $55bn investment strategy by J&J to bolster US manufacturing amid pressure from Trump.",
      "url": "https://finnhub.io/api/news?id=615a33857129581ee822ff8224aa506412088defdb6ac986dd8c38eca6a1767c"
    }
  },
  {
    "ts": null,
    "headline": "US-EU trade deal impacts on pharma industry more 'manageable' than expected",
    "summary": "A trade deal framework between the US and EU is causing less pain than anticipated for pharma.",
    "url": "https://finnhub.io/api/news?id=b2d3563e71b4a5f4a3af88b9e03d3e16afa04b85b3be2d415daa356edef90535",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755790362,
      "headline": "US-EU trade deal impacts on pharma industry more 'manageable' than expected",
      "id": 136467562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A trade deal framework between the US and EU is causing less pain than anticipated for pharma.",
      "url": "https://finnhub.io/api/news?id=b2d3563e71b4a5f4a3af88b9e03d3e16afa04b85b3be2d415daa356edef90535"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?",
    "summary": "J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.",
    "url": "https://finnhub.io/api/news?id=70167be1e6cf3fe79fb67c7dc44e2fff75d33431d09ba3d2b7bd4f75b20f772b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755782280,
      "headline": "Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?",
      "id": 136467596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.",
      "url": "https://finnhub.io/api/news?id=70167be1e6cf3fe79fb67c7dc44e2fff75d33431d09ba3d2b7bd4f75b20f772b"
    }
  },
  {
    "ts": null,
    "headline": "AUSF: The Must-Have Three-Factor ETF",
    "summary": "Discover why AUSF is a strong buy for long-term investors. Adaptive strategies, strong returns, and lower P/E make it a top choice for portfolio growth.",
    "url": "https://finnhub.io/api/news?id=42af454694d35f80f2bba23a4bf3b77a6658f23745cba7135b52c47805e96b10",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755780348,
      "headline": "AUSF: The Must-Have Three-Factor ETF",
      "id": 136467272,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2176574609/image_2176574609.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover why AUSF is a strong buy for long-term investors. Adaptive strategies, strong returns, and lower P/E make it a top choice for portfolio growth.",
      "url": "https://finnhub.io/api/news?id=42af454694d35f80f2bba23a4bf3b77a6658f23745cba7135b52c47805e96b10"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson, WH Smith, and Disney: Trending stocks",
    "summary": "J&J (JNJ) expands US domestic manufacturing, WH Smith (21Q.F) stocks plummets after accounting error and Disney (DIS) launches ESPN network. To watch more expert insights and analysis on the latest market action, check out more Morning Brief: Market Sunrise.",
    "url": "https://finnhub.io/api/news?id=79919e1b8c89fe0a89925e92d85b75cc3fdb6e02ed092085001fa075a9a50b8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755778873,
      "headline": "Johnson & Johnson, WH Smith, and Disney: Trending stocks",
      "id": 136467597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J (JNJ) expands US domestic manufacturing, WH Smith (21Q.F) stocks plummets after accounting error and Disney (DIS) launches ESPN network. To watch more expert insights and analysis on the latest market action, check out more Morning Brief: Market Sunrise.",
      "url": "https://finnhub.io/api/news?id=79919e1b8c89fe0a89925e92d85b75cc3fdb6e02ed092085001fa075a9a50b8b"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Healthcare Fund Q2 2025 Commentary",
    "summary": "The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=f8b7703fb46da00d8ea965f9f056688fcf2528cb789b78bb6f1c7c7ea46efb79",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755771900,
      "headline": "Hartford Healthcare Fund Q2 2025 Commentary",
      "id": 136458913,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/685006799/image_685006799.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=f8b7703fb46da00d8ea965f9f056688fcf2528cb789b78bb6f1c7c7ea46efb79"
    }
  },
  {
    "ts": null,
    "headline": "J&J to invest $2 billion to boost US manufacturing as drug tariffs loom",
    "summary": "Major drugmakers, including Eli Lilly and AstraZeneca, have also committed to shell out billions of dollars to scale up their U.S. footprint in response to Trump's efforts, including tariff threats.  Earlier this month, Trump said he plans to impose phased-in tariffs for the pharmaceutical sector, which could start small and eventually rise to 250%.  J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Diosynth for its more than 160,000-square-foot manufacturing facility in Holly Springs, North Carolina, which would create about 120 new jobs.",
    "url": "https://finnhub.io/api/news?id=093db7c7a1b83ad1398220f60d69b3878fd633e0969b620640780f2618e5c318",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755767496,
      "headline": "J&J to invest $2 billion to boost US manufacturing as drug tariffs loom",
      "id": 136452214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Major drugmakers, including Eli Lilly and AstraZeneca, have also committed to shell out billions of dollars to scale up their U.S. footprint in response to Trump's efforts, including tariff threats.  Earlier this month, Trump said he plans to impose phased-in tariffs for the pharmaceutical sector, which could start small and eventually rise to 250%.  J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Diosynth for its more than 160,000-square-foot manufacturing facility in Holly Springs, North Carolina, which would create about 120 new jobs.",
      "url": "https://finnhub.io/api/news?id=093db7c7a1b83ad1398220f60d69b3878fd633e0969b620640780f2618e5c318"
    }
  }
]